Thyrocare Reports ₹270.8 Crore Revenue For Q2 FY27, PAT Before Exceptional Items At ₹60.2 Crore
Mumbai: Thyrocare Technologies Limited reported consolidated revenue from operations of ₹270.8 crore for the quarter ended 30 September 2026, marking a 25.1 per cent year-on-year increase. Profit after tax (PAT) before exceptional items for the same period was ₹60.2 crore, up 25.7 per cent year-on-year. Financial Performance The company's reported EBITDA grew by 24.9 per cent year-on-year to…
Thyrocare Technologies Limited reported a 25.1% year-on-year increase in consolidated revenue from operations to ₹270.8 crore for Q2 FY27, ending 30 September 2026. Profit after tax (PAT) before exceptional items rose 25.7% year-on-year to ₹60.2 crore. EBITDA grew 24.9% to ₹89.3 crore. The Pathology segment led growth, with franchise revenue up 26.9% and partnership revenue 27.9%.
Thyrocare processed 61.6 million tests, a 27.4% year-on-year increase, with complaints down 24% and average turnaround time at 3.49 hours. The company declared a 180% interim dividend and launched a rapid Pregnancy Test Kit, endorsed by actress Yami Gautam. Thyrocare plans to divest its nuclear healthcare stake for ₹141.4 crore and acquire properties for ₹20.58 crore.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
